Zobrazeno 1 - 10
of 639
pro vyhledávání: '"gilteritinib"'
Autor:
Chuhong Hu, Yvyin Zhang, Jie Yang, Yanli Xu, Tingfen Deng, Yumiao Li, Shilin Xu, Shunqing Wang, Peihong Wang
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is a common mutation type in acute myeloid leukemia (AML) and is usually associated with poor patient prognosis. With advancements in molecular diagnostics and the
Externí odkaz:
https://doaj.org/article/8009670eecd249c4ad38edcc32956240
Autor:
Meng Zhang, Mei-Ling She, Jun Chen, Xiao-Qi Zeng, Qing-Quan Xiong, Ying-Huan Cen, Jia-An Ye, Guo-Bin Qiu, Shu-Yi Yang, Guang-Hui Ren
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 180, Iss , Pp 117603- (2024)
Multi-drug resistance (MDR) poses a significant challenge to cancer treatment. Targeting ATP-binding cassette subfamily B member 1 (ABCB1) is a viable strategy for overcoming MDR. This study examined the preclinical in vitro and animal studies that u
Externí odkaz:
https://doaj.org/article/273f1352baaf47069f41b66f52ec6cd9
Publikováno v:
Journal of Applied Pharmaceutical Research, Vol 12, Iss 2, Pp 109-123 (2024)
Background: The current investigation entails the characterization of seven degradation products (DPs) formed in different stress conditions of gilteritinib employing liquid chromatography-tandem mass spectrometry (LC-MS/MS). Methodology: This study
Externí odkaz:
https://doaj.org/article/7b07722f1edd4a6ca1360ed68e558a57
Autor:
Karam Ashouri, Krithika Chennapan, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Anush Aram Ginosyan, Eric Tam, Abdullah Ladha, Karrune Woan, Preet Chaudhary, Imran Siddiqi, George Yaghmour
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 423-427 (2024)
Externí odkaz:
https://doaj.org/article/275e3b98e2f440e8abd653b714c3971f
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTBackground: Acute febrile neutrophilic dermatosis, also commonly referred to as Sweet syndrome, is often associated with tumors, infections, immune disorders and medications. FLT3 inhibitor-induced Sweet syndrome is a rare complication.Method
Externí odkaz:
https://doaj.org/article/78b728f6d0c9487badd2806770627ba9
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTObjective: Extramedullary relapse (EMR) is rare in acute promyelocytic leukemia (APL) and, there is a lack of information on its management. Current practices for EMR in APL are always to adopt strategies from other subtypes of Acute lymphobl
Externí odkaz:
https://doaj.org/article/fc78f18c7ef54d06b5baf47e66b46a1d
Autor:
Man Li, Xiawan Yang, Yaonan Hong, Qi Liu, Yingying Shen, Tonglin Hu, Yiping Shen, Guoyin Kai, Dijiong Wu
Publikováno v:
Heliyon, Vol 10, Iss 16, Pp e35847- (2024)
Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment. In this report, a relapsed/refractory (R/R) venetoclax resistant AML1-
Externí odkaz:
https://doaj.org/article/a67f3981d4694653ba18086bd3a6cda1
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
FLT3-ITD is a type of poor prognostic factors in acute myeloid leukemia (AML) disease. Gilteritinib, the second-generation FLT3 tyrosine kinase inhibitor, improved the overall survival of patients with relapsed/refractory FLT3-mutated AML in the ADMI
Externí odkaz:
https://doaj.org/article/dc73fdbc10a1458bb84ffdebd0482c4b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Malia E. Leifheit, Gunnar Johnson, Timothy M. Kuzel, Jeffrey R. Schneider, Edward Barker, Hyun D. Yun, Celalettin Ustun, Josef W. Goldufsky, Kajal Gupta, Amanda L. Marzo
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 17, p 9448 (2024)
FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML represent a challenging clinical scenario characterized by a high rate of relap
Externí odkaz:
https://doaj.org/article/455f4acfc0814fb398f937c9f256145a